- Home
- BIAF vs DUKRW Comparison
BIAF vs DUKRW Comparison
Compare BIAF & DUKRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | DUKRW |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Israel |
| Employees | 57 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BIAF | DUKRW |
|---|---|---|
| Price | $0.60 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 298.8K | 5.2K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.10 |
| 52 Week High | $13.50 | $1.59 |
Technical Indicators
Market Signals| Indicator | BIAF | DUKRW |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 41.38 |
| Support Level | N/A | $0.88 |
| Resistance Level | $0.87 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 29.84 | 57.05 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.